> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss 2 sNDAs for Diabetes
- URL: https://www.fdaweb.com/panel-to-discuss-2-sndas-for-diabetes/
- Published: 2016-05-18T12:00:00.000Z
- Updated: 2026-09-14T21:03:50.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135700

*Federal Register* Notice: FDA will hold a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee 6/28, from 8 a.m. to 5 p.m., at Hilton Washington DC/Rockville Hotel & Executive Meeting Center, Plaza Ballroom, 1750 Rockville Pike, Rockville, MD. The committee will discuss two Boehringer Ingelheim Pharmaceuticals supplemental NDAs for Jardiance (empagliflozin) tablets and Synjardy (empagliflozin and metformin hydrochloride) tablets. They are for the proposed additional indication in adult patients with Type 2 diabetes mellitus and high cardiovascular risk to reduce the risk of all-cause mortality by reducing the incidence of cardiovascular death and to reduce the risk of cardiovascular death or hospitalization for heart failure. Contact **LaToya Bonner**, (301) 796-9001\. To view this notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2016-05-18/pdf/2016-11678.pdf?ref=fdaweb.com).